CMS Sleep Testing for OSA Coverage Policy Update (NCD 330) — What Billing Teams Need to Know
CMS has modified its National Coverage Determination for sleep testing related to obstructive sleep apnea under NCD 330, with an effective date of March 12, 2026. This update governs which diagnostic sleep testing technologies qualify as reasonable and necessary under Medicare, directly affecting how sleep labs, pulmonology practices, and related specialties bill for OSA workups. If your organization performs or bills for polysomnography or portable home sleep testing, this policy modification warrants a careful review before the effective date.
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Sleep Testing for Obstructive Sleep Apnea (OSA) |
| Policy Code | NCD 330 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | High |
| Specialties Affected | Sleep medicine, pulmonology, neurology, otolaryngology, primary care ordering physicians, sleep lab facilities |
| Key Action | Audit your OSA diagnostic testing protocols and documentation practices to confirm alignment with the four covered device type categories before claims hit with dates of service on or after March 12, 2026. |
CMS OSA Diagnostic Testing Coverage: What NCD 330 Actually Says
The Centers for Medicare & Medicaid Services established national covered indications for OSA sleep testing effective for claims with dates of service on and after March 3, 2009 — and the 2026 modification to NCD 330 carries those foundational coverage rules forward while refining how they apply across device types.
The policy distinguishes between four types of diagnostic sleep testing technologies. Understanding exactly where each type sits within the coverage framework is essential for clean claims and defensible documentation.
Type I Polysomnography (PSG): The Reference Standard
Type I attended facility-based polysomnography remains the most comprehensive covered test under this NCD. To qualify, it must be:
- Performed attended in a sleep lab facility — unattended Type I PSG is not covered
- Comprehensive in scope — must include at minimum: electroencephalography (EEG), electro-oculography (EOG), electromyography (EMG), heart rate or ECG, airflow, breathing/respiratory effort, and arterial oxygen saturation (SaO₂)
- Supervised by a technologist during sleep time, with the ability to intervene if needed
The American Thoracic Society and the American Academy of Sleep Medicine have both recommended supervised PSG in the sleep laboratory over two nights for OSA diagnosis and CPAP initiation — and CMS coverage aligns with that clinical guidance.
Type II and Type III Portable Monitors: Flexible Coverage Settings
Type II and Type III devices are covered under more flexible conditions than Type I. Both types can be used attended or unattended, in or out of a sleep lab facility.
- Type II monitors require a minimum of seven channels — including EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort, and SaO₂. Because Type II devices monitor sleep staging, the apnea-hypopnea index (AHI) can be calculated directly.
- Type III monitors require a minimum of four channels: ventilation or airflow (at minimum two channels of respiratory movement, or respiratory movement and airflow), heart rate or ECG, and oxygen saturation.
The covered indication for both: the beneficiary must have clinical signs and symptoms indicative of OSA. That documentation of clinical indication is non-negotiable for Medicare claims.
Type IV Devices: Coverage Depends on Channel Count
Type IV devices — which may measure one, two, three, or more parameters but don't meet the criteria of a higher-category device — are only covered under a specific condition:
Coverage applies only when the Type IV device measures three or more channels, one of which is airflow.
A Type IV device measuring fewer than three channels, or three or more channels that do not include airflow, falls outside covered indications. This is a bright line that your documentation and device selection must respect.
Actigraphy-Based Devices: The Fourth Covered Category
CMS also covers sleep testing devices measuring three or more channels that include actigraphy, oximetry, and peripheral arterial tone — when used to diagnose OSA in beneficiaries with signs and symptoms indicative of OSA. These devices may be used attended or unattended, in or out of a sleep lab.
This coverage pathway is particularly relevant for home sleep apnea testing (HSAT) workflows using peripheral arterial tonometry technology.
Non-Covered OSA Diagnostic Tests Under NCD 330
Any diagnostic sleep tests for OSA that fall outside the four nationally covered categories listed above are non-covered under this NCD, effective for claims with dates of service on and after March 3, 2009. This includes Type IV devices that do not meet the three-channel/airflow threshold.
CMS's position is that the evidence for other diagnostic approaches is insufficient to determine that results can reliably be used by a treating physician to diagnose OSA and demonstrate improved health outcomes in Medicare beneficiaries.
Medical Necessity Documentation Requirements
Across all four covered device types, the threshold criterion is consistent: the beneficiary must have clinical signs and symptoms indicative of OSA. This language is load-bearing for your billing team. A claim lacking documented clinical indication — regardless of the device type used — creates audit exposure.
Ordering physicians should be documenting relevant signs and symptoms (daytime sleepiness, witnessed apneas, snoring, comorbidities like obesity or hypertension that increase OSA risk) in the medical record before the test is ordered. That documentation needs to flow through to your billing team's pre-claim review process.
The policy does not specify prior authorization requirements within the NCD itself, but MACs (Medicare Administrative Contractors) may impose prior authorization or prior determination requirements through Local Coverage Determinations (LCDs). Billing teams should verify requirements with their specific MAC jurisdiction.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
This policy does not list specific CPT, HCPCS, or ICD-10 codes within the data provided for this policy version. Billing teams should cross-reference this NCD with applicable MAC LCDs, which typically enumerate the specific CPT codes (such as those in the 95800–95811 range commonly associated with polysomnography and HSAT) and relevant ICD-10 diagnosis codes (such as G47.33 for obstructive sleep apnea) that govern local billing requirements.
Check your MAC's LCD and billing and coding article for the complete code list that operationalizes this NCD in your jurisdiction.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Before March 12, 2026 — audit your device type documentation. Pull a sample of recent OSA diagnostic claims and confirm that the device type used (I, II, III, or qualifying Type IV/actigraphy) is clearly documented in the ordering records and mapped correctly to your billing. Any Type IV claims should be verified to confirm the device measured three or more channels including airflow. |
| 2 | Immediately — update clinical sign and symptom documentation protocols. Work with your sleep lab medical director and ordering physicians to ensure that pre-test documentation consistently captures clinical indicators of OSA. This is the universal coverage requirement across all four device types and the most common gap in audit findings. |
| 3 | This week — verify MAC LCD requirements for your jurisdiction. Since NCD 330 does not enumerate specific CPT or ICD-10 codes, contact your MAC or review their published LCD to confirm which procedure codes are recognized locally and whether any prior authorization or prior determination requirements apply in your region. |
| 4 | Before the effective date — train front-end staff on the attended/unattended distinction. Type I PSG coverage requires attended administration in a sleep lab — this is a hard requirement. Staff scheduling tests or obtaining orders need to understand that unattended Type I studies do not qualify for Medicare coverage under this NCD. |
| 5 | Ongoing — flag any new OSA testing technologies before billing. If your practice is evaluating or piloting newer home sleep testing devices, confirm that the device meets one of the four covered categories before billing Medicare. Devices that don't fit cleanly into Type I–IV designations or the actigraphy/oximetry/peripheral arterial tone framework will likely be non-covered. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.